RCKTRocket Pharmaceuticals, Inc.
3.510USD+0.86%Mkt Cap: 385.31M $P/E: —3d ago
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases i…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps. | ||
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says Rocket Pharmaceuticals' (RCKT) Q2 update confirmed its programs are on track, with management expect | MMT Newswires | |
IInsider Monkey | ||